Skip to main content
SpringerLink
Log in

Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Galldiks N, Albert NL, Sommerauer M, Grosu AL, Ganswindt U, Law I, et al. PET imaging in patients with meningioma-report of the RANO/PET group. Neuro Oncol. 2017;19:1576–87. https://doi.org/10.1093/neuonc/nox112.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016;17:e383–91. https://doi.org/10.1016/S1470-2045(16)30321-7.

    Article  PubMed  Google Scholar 

  3. Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol. 2014;16:829–40. https://doi.org/10.1093/neuonc/not330.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35. https://doi.org/10.1056/NEJMoa1607427.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Graillon T, Romano D, Defilles C, Saveanu A, Mohamed A, Figarella-Branger D, et al. Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review. J Neurosurg. 2017;127:660–9. https://doi.org/10.3171/2016.8.JNS16995.

    Article  CAS  PubMed  Google Scholar 

  6. Soto-Montenegro ML, Peña-Zalbidea S, Mateos-Pérez JM, Oteo M, Romero E, Morcillo M, et al. Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice. PLoS One. 2014;9:e111624. https://doi.org/10.1371/journal.pone.0111624.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Sommerauer M, Burkhardt JK, Frontzek K, Rushing E, Buck A, Krayenbuehl N, et al. 68Gallium-DOTATATE PET in meningioma: a reliable predictor of tumor growth rate? Neuro Oncol. 2016;18:1021–7. https://doi.org/10.1093/neuonc/now001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Gerster-Gilliéron K, Forrer F, Maecke H, Mueller-Brand J, Merlo A, Cordier D. 90Y-DOTATOC as a therapeutic option for complex recurrent or progressive meningiomas. J Nucl Med. 2015;56:1748–51. https://doi.org/10.2967/jnumed.115.155853.

    Article  CAS  PubMed  Google Scholar 

  9. Marincek N, Radojewski P, Dumont RA, Brunner P, Müller-Brand J, Maecke HR, et al. Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial. J Nucl Med. 2015;56:171–6. https://doi.org/10.2967/jnumed.114.147256.

    Article  CAS  PubMed  Google Scholar 

  10. Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E, et al. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging. 2009;36:1407–16. https://doi.org/10.1007/s00259-009-1115-z.

    Article  CAS  PubMed  Google Scholar 

  11. Sabet A, Ahmadzadehfar H, Herrlinger U, Wilinek W, Biersack HJ, Ezziddin S. Successful radiopeptide targeting of metastatic anaplastic meningioma: case report. Radiat Oncol. 2011;6:94. https://doi.org/10.1186/1748-717X-6-94.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Seystahl K, Stoecklein V, Schüller U, Rushing E, Nicolas G, Schäfer N, et al. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. Neuro Oncol. 2016;18:1538–47. https://doi.org/10.1093/neuonc/now060.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med. 2006;47:1599–606.

    PubMed  Google Scholar 

  14. Kreissl MC, Hänscheid H, Löhr M, Verburg FA, Schiller M, Lassmann M, et al. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiat Oncol. 2012;7:99. https://doi.org/10.1186/1748-717X-7-99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Backhaus P, Huss S, Kösek V, Weckesser M, Rahbar K. Lung metastases of intracranial atypical meningioma diagnosed on post therapeutic imaging after 177Lu-DOTATATE therapy. Clin Nucl Med. 2018;43:e184–5. https://doi.org/10.1097/RLU.0000000000002077.

    Article  PubMed  Google Scholar 

  16. Cremonesi M, Ferrari ME, Bodei L, Chiesa C, Sarnelli A, Garibaldi C, et al. Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning. Eur J Nucl Med Mol Imaging. 2018;45:2426–41. https://doi.org/10.1007/s00259-018-4044-x.

    Article  CAS  PubMed  Google Scholar 

  17. Sandström M, Garske-Román U, Granberg D, Johansson S, Widström C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54:33–41. https://doi.org/10.2967/jnumed.112.107524.

    Article  CAS  PubMed  Google Scholar 

  18. Sundlöv A, Sjögreen-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, et al. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017;44:1480–9. https://doi.org/10.1007/s00259-017-3678-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Del Prete M, Buteau FA, Beauregard JM. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. Eur J Nucl Med Mol Imaging. 2017;44:1490–500. https://doi.org/10.1007/s00259-017-3688-2.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was conducted in the framework of DHU-Imaging thanks to the support of the A*MIDEX project (no. ANR-11-IDEX-0001-02) (Investissements d’Avenir French Government programme, managed by the French National Research Agency, ANR).

Author information

Authors and Affiliations

  1. Service de Médecine Nucléaire, CHU Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France

    Eric Guedj & David Taieb

  2. CNRS, Ecole Centrale Marseille, UMR 7249, Institut Fresnel, Aix-Marseille Université, Marseille, France

    Eric Guedj

  3. CERIMED, Aix-Marseille Université, Marseille, France

    Eric Guedj & David Taieb

  4. Service de Neurochirurgie, CHU Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France

    Thomas Graillon

  5. CNRS, UMR7286, CRN2M, Aix-Marseille Université, Marseille, France

    Thomas Graillon

  6. Service de Neuro-Oncologie, CHU Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France

    Olivier Chinot

  7. Inserm, U1068-CNRS 7258, Cancer Research Center of Marseille, Aix-Marseille Université, Marseille, France

    David Taieb

Authors
  1. Eric Guedj
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Graillon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Olivier Chinot
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David Taieb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric Guedj.

Ethics declarations

Conflicts of interest

None.

Ethical approval

This article does not describe any studies with human participants performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guedj, E., Graillon, T., Chinot, O. et al. Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 46, 537–538 (2019). https://doi.org/10.1007/s00259-018-4221-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-018-4221-y

Search

Navigation